Noriyoshi Iriyama

17PUBLICATIONS
44CO-AUTHORS
Medical mycologyPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Sep 03, 2026
Evaluation of the UK Myeloma Research Alliance risk profile in transplant-ineligible multiple myeloma patients treated with novel agents.

|Aug 14, 2026
ELTS Score and Early "Warning" Define a Two-Stage Risk Framework for Failure-Free Survival in Chronic-Phase CML.

|Jul 09, 2026
Reattempt of tyrosine kinase inhibitor discontinuation after maintenance therapy with ponatinib in patients with chronic myeloid leukaemia in the chronic phase: Result of the Japan Adult Leukemia Study Group RE-STOP219 study.

|Jun 18, 2026
Treatment-free remission and immune profiling after frontline second-generation TKI therapy in CML.

|Jun 11, 2026
Early predictors of MR4.5 attainment and eligibility for TKI discontinuation in CML treated with second-generation TKIs.

|Nov 09, 2025
Favorable response to daratumumab combination therapy in patients with multiple myeloma with an immature phenotype: a report from the J-CHARGE study group.

Noriyoshi Iriyama, Hitomi Nakayama, Masaru Nakagawa

Pageof 3

Frequent Collaborators

5 joint publications

Emiko Sakaida

5 joint publications

Naoto Takahashi

4 joint publications

Hitoshi Kiyoi

4 joint publications

Takaaki Ono